Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-06-28
2011-06-28
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S009200, C424S185100, C424S234100, C536S023100, C536S023700
Reexamination Certificate
active
07968105
ABSTRACT:
The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens fromM. tuberculosis, the units of the fusion polypeptide beingM. tuberculosisantigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
REFERENCES:
patent: 6485914 (2002-11-01), Izutsu et al.
patent: 6641814 (2003-11-01), Andersen et al.
patent: WO 01/23388 (2001-04-01), None
patent: WO 01/79274 (2001-10-01), None
patent: WO 03//004520 (2003-01-01), None
patent: WO 2004/006952 (2004-01-01), None
patent: WO 2004/083448 (2004-09-01), None
Andersen, P. et al., “Simultaneous electroelution of whole SDS-polyacrylamide gels for the direct cellular analysis of complex protein mixtures” 1993, J. Immunol. Methods 161, pp. 29-39.
Andersen, P. et al., “Proteins Released fromMycobacterium tuberculosisduring Growth” 1991, Infect. Immun. 59, pp. 1905-1910.
Betts, J. et al., “Evaluation of a nutrient starvation model ofMycobacterium tuberculosispersistence by gene and protein expression profiling” 2002, Molecular Microbiology, 43, pp. 717-731.
Brandt, L. et al., “ESAT-6 Subunit Vaccination againstMycobacterium tuberculosis” 2000 Infect. Immun. 68:2, pp. 791-795.
Brooks, J.V., et al., “Boosting Vaccine for Tuberculosis” Infect. Immun 2001, 69(4), pp. 2714-2717.
Colditz, G.A., et al., “Efficacy of BCG Vaccine in the Prevention of Tuberculosis” JAMA 1994, 271, pp. 698-702.
Cole, S.T. et al., “Deciphering the biology ofMycobacterium tuberculosisfrom the complete genome sequence” 1998 Nature 393, pp. 537-544.
Cote-Sierra J. et al., “A new membrane-bound Oprl lipoprotein expression vector High production of heterologous fusion proteins in Gram (−) bacteria and the implications for oral vaccination” 1998, Gene Oct 9, 221(1), pp. 25-34.
Gosselin, E. et al., “Enhanced Antigen Presentation using Human Fcy Receptor (Monocyte/Macrophage)-Specific Immunogens” 1992, J. Immunol. 149, pp. 3477-3481.
Harboe, M. et al., “B-Cell Epitopes and Quantification of the ESAT-6 Protein ofMycobacterium tuberculosis” 1998, Infect. Immun. 66:2, pp. 717-723.
Lowrie, D.B. et al., “Therapy of tuberculosis in mice by DNA vaccination” 1999, Nature, 400, pp. 269-271.
Lyashchenko, K.P. et al., “A multi-antigen print immunoassay for the development of serological diagnosis of infectious diseases” 2000, J. Immunological Methods 242, pp. 91-100.
Nagai, S. et al., “Isolation and Partial Characterization of Major Protein Antigens in the Culture Fluid ofMycobacterium tuberculosis” 1991, Infect. Immun. 59:1, pp. 372-382.
Pollock, J. et al, “Assessment of defined antigens for the diagnosis of bovine tuberculosis in skin test-reactor cattle” 2000, The Veterinary record, 146, pp. 659-665.
Rolph, M.S. et al., “Recombinant viruses as vaccines and immunological tools” 1997, Curr. Opin. Immunol. 9, pp. 517-524.
Rosenkrands, I. et al., “Identification and Characterization of a 29-Kilodalton Protein fromMycobacterium tuberculosisCulture Filtrate Recognized by Mouse Memory Effector Cells” 1998, Infect. Immun. 66:6, pp. 2728-2735.
Sherman, D.R. et al., Regulation of theMycobacterium tuberculosishypoxic response gene encoding alpha-crystallin 2001 Proc Natl Acad Sci USA 98, pp. 7534-7539.
Skjot, R.L.V. et al., “Comparative Evaluation of Low-Molecular-Mass Proteins fromMycobacterium tuberculosisIdentifies Members of the ESAT-6 Family as Immunodominant T-Cell Antigens” 2000, Infect. Immun. 68:1, pp. 214-220.
Stryhn, A. et al., “Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding” 1996 Eur. J. Immunol. 26, pp. 1911-1918.
Thompson J. et al., “Clustal W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice” Nucleic Acids Res. 1994, 22, pp. 4673-4680.
Olsen A. W, et al., “Efficient protection againstMycobacterium tuberculosisby vaccination with a single subdominant epitope from the ESAT-6 antigen” Eur. J. Immunol. Jun. 2000, 30(6), pp. 1724-1732.
Theisen, M., et al., “Antigenicity and Immunogenicity of Recombinant Glutamate-Rich Protein of Plasmodium falciparum Expressed inEscherichia coli” 1995, Clin. Diagn. Lab. Immunol. 2(1), pp. 30-34.
Ravn, P. et al., “Human T Cell Responses to the ESAT-6 Antigen fromMycobacterium tuberculosis” 1999, J. Infect. Dis. 179, pp. 637-645.
Kilgus J. et al., “Analysis of the Permissive Association of a Malaria T Cell Epitope with DR Molecules” J. Immunol., Jan. 1, 1991, 146(1), pp. 307-315.
Sinigaglia, F. et al., “A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules” Nature, Dec. 22-29, 1988, 336(6201), pp. 778-780.
Pearson W.R. et al., “Improved tools for biological sequence comparison” 1988, PNAS USA 85, pp. 2444-2448.
Köhler G. et al., “Continuous cultures of fused cells secreting antibody of predefined specificity” Nature, 1975, 256, pp. 495-497.
McCafferty J. et al., “Phage antibodies: filamentous phage displaying antibody variable domains” 1990, Nature, 348, pp. 552-554.
Merrifield, R.B., “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide” 1963, J. Am. Chem. Soc. 85 (14), pp. 2149-2154.
Mowat, A.M. et al., “Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route” 1991, Immunology 72(3), pp. 317-322.
Lustig J.V. et al., “Humoral and Cellular Responses to Native Antigen following Oral and Parenteral Immunization with Lipid-Conjugated Bovine Serum Albumin” 1976, Cell Immunol. 24(1), pp. 164-172.
Olsen A. W. et al., “Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6” Infection and Immunity, American Society for Microbiology, vol. 69, No. 5, May 2001, pp. 2773-2778.
Dietrich J. et al., “Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy” Journal of immunology, vol. 174, No. 10, May 2005, pp. 6332-6339.
Leyten E. et al., “Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon ofMycobacterium tuberculosis” Microbes and Infection, Elsevier, Paris, FR, vol. 8, No. 8, Jul. 2006, pp. 2052-2060.
Agger E. M. et al., “Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31” Vaccine, Butterworth Scientific. Guildford, GB, vol. 24, No. 26, Jun. 29, 2006, pp. 5452-5460.
Turner, Joanne et al., “Effective Preexposure Tuberculosis Vaccines Fail to Protect When They Are Given in an Immunotherapeutic Mode” Infection and Immunity, Mar. 2000, p. 1706-1709, vol. 68, No. 3.
Database UniProt, “Subname:Full=Putative uncharacterized protein” Feb. 1, 1997, XP002563173.
Database UniProt, “Subname:Full=Putative uncharacterized protein Mb2678c;” Oct. 1, 2003, XP002563174.
Aagaard Claus
Andersen Peter
Vingsbo-Lundberg Carina
Knobbe Martens Olson & Bear LLP
Statens Serum Institut
Swartz Rodney P.
LandOfFree
Tuberculosis vaccines comprising antigens expressed during... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tuberculosis vaccines comprising antigens expressed during..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tuberculosis vaccines comprising antigens expressed during... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742585